An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population
**Background:** Traditional health economic evaluations of antimicrobials currently underestimate their value to wider society. They can be supplemented by additional value elements including insurance value, which captures the value of an antimicrobial in preventing or mitigating impacts of adverse...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2023-07-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.75206 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860314149486592 |
|---|---|
| author | Mei S. Chan Richard Holloway Robert King Rosie Polya Rebecca Sloan Jack C. Kowalik Tom Ashfield Luke S.P. Moore Thomas Porter Jonathan Pearson-Stuttard |
| author_facet | Mei S. Chan Richard Holloway Robert King Rosie Polya Rebecca Sloan Jack C. Kowalik Tom Ashfield Luke S.P. Moore Thomas Porter Jonathan Pearson-Stuttard |
| author_sort | Mei S. Chan |
| collection | DOAJ |
| description | **Background:** Traditional health economic evaluations of antimicrobials currently underestimate their value to wider society. They can be supplemented by additional value elements including insurance value, which captures the value of an antimicrobial in preventing or mitigating impacts of adverse risk events. Despite being commonplace in other sectors, constituents of the impacts and approaches for estimating insurance value have not been investigated.
**Objectives:** This study assessed the insurance value of a novel gram-negative antimicrobial from operational healthcare, wider population health, productivity, and informal care perspectives.
**Methods:** A novel mixed-methods approach was used to model insurance value in the United Kingdom: (1) literature review and multidisciplinary expert workshops to identify risk events for 4 relevant scenarios: ward closures, unavoidable shortage of conventional antimicrobials, viral respiratory pandemics, and catastrophic antimicrobial resistance (AMR); (2) parameterizing mitigable costs and frequencies of risk events across perspectives and scenarios; (3) estimating insurance value through a Monte Carlo simulation model for extreme events and a dynamic disease transmission model.
**Results:** The mean insurance value across all scenarios and perspectives over 10 years in the UK was £718 million, should AMR remain unchanged, where only £134 million related to operational healthcare costs. It would be 50%-70% higher if AMR steadily increased or if a more risk-averse view (1-in-10 year downside) of future events is taken.
**Discussion:** The overall insurance value if AMR remains at current levels (a conservative projection), is over 5 times greater than insurance value from just the operational healthcare costs perspective, traditionally the sole perspective used in health budgeting. Insurance value was generally larger for nationwide or universal (catastrophic AMR, pandemic, and conventional antimicrobial shortages) rather than localized (ward closure) scenarios, across perspectives. Components of this insurance value match previously published estimates of operational costs and mortality impacts.
**Conclusions:** Insurance value of novel antimicrobials can be systematically modeled and substantially augments their traditional health economic value in normal circumstances. These approaches are generalizable to similar health interventions and form a framework for health systems and governments to capture broader value in health technology assessments, improve healthcare access, and increase resilience by planning for adverse scenarios. |
| format | Article |
| id | doaj-art-de997ad8ecf14f9daa1954840b79abb7 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-de997ad8ecf14f9daa1954840b79abb72025-02-10T16:13:36ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362023-07-01102An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the PopulationMei S. ChanRichard HollowayRobert KingRosie PolyaRebecca SloanJack C. KowalikTom AshfieldLuke S.P. MooreThomas PorterJonathan Pearson-Stuttard**Background:** Traditional health economic evaluations of antimicrobials currently underestimate their value to wider society. They can be supplemented by additional value elements including insurance value, which captures the value of an antimicrobial in preventing or mitigating impacts of adverse risk events. Despite being commonplace in other sectors, constituents of the impacts and approaches for estimating insurance value have not been investigated. **Objectives:** This study assessed the insurance value of a novel gram-negative antimicrobial from operational healthcare, wider population health, productivity, and informal care perspectives. **Methods:** A novel mixed-methods approach was used to model insurance value in the United Kingdom: (1) literature review and multidisciplinary expert workshops to identify risk events for 4 relevant scenarios: ward closures, unavoidable shortage of conventional antimicrobials, viral respiratory pandemics, and catastrophic antimicrobial resistance (AMR); (2) parameterizing mitigable costs and frequencies of risk events across perspectives and scenarios; (3) estimating insurance value through a Monte Carlo simulation model for extreme events and a dynamic disease transmission model. **Results:** The mean insurance value across all scenarios and perspectives over 10 years in the UK was £718 million, should AMR remain unchanged, where only £134 million related to operational healthcare costs. It would be 50%-70% higher if AMR steadily increased or if a more risk-averse view (1-in-10 year downside) of future events is taken. **Discussion:** The overall insurance value if AMR remains at current levels (a conservative projection), is over 5 times greater than insurance value from just the operational healthcare costs perspective, traditionally the sole perspective used in health budgeting. Insurance value was generally larger for nationwide or universal (catastrophic AMR, pandemic, and conventional antimicrobial shortages) rather than localized (ward closure) scenarios, across perspectives. Components of this insurance value match previously published estimates of operational costs and mortality impacts. **Conclusions:** Insurance value of novel antimicrobials can be systematically modeled and substantially augments their traditional health economic value in normal circumstances. These approaches are generalizable to similar health interventions and form a framework for health systems and governments to capture broader value in health technology assessments, improve healthcare access, and increase resilience by planning for adverse scenarios.https://doi.org/10.36469/001c.75206 |
| spellingShingle | Mei S. Chan Richard Holloway Robert King Rosie Polya Rebecca Sloan Jack C. Kowalik Tom Ashfield Luke S.P. Moore Thomas Porter Jonathan Pearson-Stuttard An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population Journal of Health Economics and Outcomes Research |
| title | An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population |
| title_full | An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population |
| title_fullStr | An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population |
| title_full_unstemmed | An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population |
| title_short | An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population |
| title_sort | insurance value modeling approach that captures the wider value of a novel antimicrobial to health systems patients and the population |
| url | https://doi.org/10.36469/001c.75206 |
| work_keys_str_mv | AT meischan aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT richardholloway aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT robertking aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT rosiepolya aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT rebeccasloan aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT jackckowalik aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT tomashfield aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT lukespmoore aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT thomasporter aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT jonathanpearsonstuttard aninsurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT meischan insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT richardholloway insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT robertking insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT rosiepolya insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT rebeccasloan insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT jackckowalik insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT tomashfield insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT lukespmoore insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT thomasporter insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation AT jonathanpearsonstuttard insurancevaluemodelingapproachthatcapturesthewidervalueofanovelantimicrobialtohealthsystemspatientsandthepopulation |